Should I buy or sell AbCellera Biologics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABCL shares. View ABCL analyst ratings or view top-rated stocks .

What is AbCellera Biologics' stock price target for 2024?

11 brokerages have issued 1 year target prices for AbCellera Biologics' shares. Their ABCL share price targets range from $6.00 to $34.00. On average, they expect the company's stock price to reach $20.11 in the next year. This suggests a possible upside of 317.2% from the stock's current price. View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts .

How have ABCL shares performed in 2023?

AbCellera Biologics' stock was trading at $10.13 at the start of the year. Since then, ABCL shares have decreased by 52.4% and is now trading at $4.82. View the best growth stocks for 2023 here .

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our ABCL earnings forecast .

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) announced its earnings results on Thursday, November, 2nd. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company earned $6.60 million during the quarter, compared to analysts' expectations of $11.92 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 10.72% and a negative net margin of 256.27%.

What ETFs hold AbCellera Biologics' stock?

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM) . TrueShares Technology, AI & Deep Learning ETF (LRNZ) .

When did AbCellera Biologics IPO?

(ABCL) raised $356 million in an IPO on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

Who are AbCellera Biologics' major shareholders?

AbCellera Biologics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (9.03%), Federated Hermes Inc. (1.12%), Lazard Asset Management LLC (1.08%), American Century Companies Inc. (0.33%), Royal Bank of Canada (0.14%) and Schonfeld Strategic Advisors LLC (0.12%). Insiders that own company stock include Andrew Booth , Andrew Lo , Carl L G Hansen , Holdings Ltd Thermopylae, John Hamer , John S Montalbano , Michael R Hayden and Veronique Lecault . View institutional ownership trends .

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

AbCellera Biologics Stock Price, News & Analysis (NASDAQ:ABCL)

$4.87

+0.03 (+0.62%)

(As of 12/8/2023 ET)

Compare

Today's Range: $4.70
▼
$4.97
50-Day Range: $3.91
▼
$4.85
52-Week Range: $3.87
▼
$11.38

Volume: 1.52 million shs
Average Volume: 2.06 million shs
Market Capitalization: $1.41 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.11

AbCellera Biologics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.91 Rating Score
Upside/Downside: 317.2% Upside
$20.11 Price Target
Short Interest: Bearish
13.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.31
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.48) to ($0.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

450th out of 960 stocks

Pharmaceutical Preparations Industry

162nd out of 372 stocks

4.5

Analyst's Opinion

Consensus Rating
AbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.11, AbCellera Biologics has a forecasted upside of 317.2% from its current price of $4.82.
Amount of Analyst Coverage
AbCellera Biologics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
13.87% of the float of AbCellera Biologics has been sold short.
Short Interest Ratio / Days to Cover
AbCellera Biologics has a short interest ratio ("days to cover") of 17.8, which indicates bearish sentiment.
Change versus previous month
Short interest in AbCellera Biologics has recently decreased by 1.22%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
AbCellera Biologics does not currently pay a dividend.
Dividend Growth
AbCellera Biologics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABCL.

1.8

News and Social Media Coverage

News Sentiment
AbCellera Biologics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.
Search Interest
Only 14 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.
MarketBeat Follows
Only 13 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -32% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbCellera Biologics insiders have not sold or bought any company stock.
Percentage Held by Insiders
32.45% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
47.39% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.48) to ($0.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbCellera Biologics is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbCellera Biologics is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AbCellera Biologics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AbCellera Biologics Stock (NASDAQ:ABCL)

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABCL Stock News Headlines

December 8, 2023 | seekingalpha.com

AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024

December 8, 2023 | americanbankingnews.com

KeyCorp Weighs in on AbCellera Biologics Inc.'s FY2023 Earnings (NASDAQ:ABCL)

December 8, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 7, 2023 | seekingalpha.com

Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform

December 6, 2023 | americanbankingnews.com

AbCellera Biologics (NASDAQ:ABCL) Now Covered by Analysts at KeyCorp

December 6, 2023 | americanbankingnews.com

Analysts Set AbCellera Biologics Inc. (NASDAQ:ABCL) PT at $21.88

December 3, 2023 | americanbankingnews.com

AbCellera Biologics (NASDAQ:ABCL) Shares Down 3.4%

December 3, 2023 | americanbankingnews.com

Comparing AbCellera Biologics (NASDAQ:ABCL) & Adicet Bio (NASDAQ:ACET)

December 8, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 2, 2023 | markets.businessinsider.com

Leerink Partners Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)

November 30, 2023 | theglobeandmail.com

AbCellera cuts 10 per cent of staff as biotech slump hits Vancouver antibody developer

November 29, 2023 | theglobeandmail.com

Cutting-edge antibody therapy firm AbCellera to lay off 10% of work force

November 24, 2023 | finance.yahoo.com

AbCellera Biologics Insiders Added US$2.47m Of Stock To Their Holdings

November 22, 2023 | morningstar.com

AbCellera Biologics Inc Ordinary Shares

November 9, 2023 | benzinga.com

AbCellera Biologics Director Trades Company's Stock

November 3, 2023 | finance.yahoo.com

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

November 3, 2023 | finance.yahoo.com

AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript

November 3, 2023 | finance.yahoo.com

Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress

November 2, 2023 | finance.yahoo.com

AbCellera Biologics Inc (ABCL) Reports Q3 2023 Earnings: Revenue Drops to $7 Million

November 2, 2023 | finance.yahoo.com

AbCellera Reports Q3 2023 Business Results

October 26, 2023 | finance.yahoo.com

Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to Decline

October 16, 2023 | realmoney.thestreet.com

Small-Cap Biotech Needs Some Emergency Care

October 13, 2023 | markets.businessinsider.com

AbCellera Biologics: Promising Investment in Antibody Therapeutics Backed by Proprietary Discovery Engine and Strategic Partnerships

October 11, 2023 | finance.yahoo.com

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

September 27, 2023 | benzinga.com

Board Member of AbCellera Biologics Purchased $98K In Stock

September 25, 2023 | seekingalpha.com

AbCellera's Clinical Carousel: High Risk, Higher Stakes

September 20, 2023 | finance.yahoo.com

AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron

See More Headlines

Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ABCL
CUSIP: N/A
CIK: 1703057
Web: www.abcellera.com
Phone: 604-559-9005
Fax: N/A
Employees: 630
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.11
High Stock Price Target: $34.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +313.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.91
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $158.52 million
Net Margins: -256.27%
Pretax Margin: -311.24%
Return on Equity: -10.72%
Return on Assets: -8.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.34
Quick Ratio: 8.34

Sales & Book Value

Annual Sales: $485.42 million
Price / Sales: 2.91
Cash Flow: $0.68 per share
Price / Cash Flow: 7.21
Book Value: $4.31 per share
Price / Book: 1.13

Miscellaneous

Outstanding Shares: 290,170,000
Free Float: 196,010,000
Market Cap: $1.41 billion
Optionable: Not Optionable
Beta: 0.28

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Carl L.G. Hansen Ph.D. (Age 48)
CEO, President & Chairperson
Comp: $711.47k
Mr. Andrew Booth M.B.A. (Age 49)
Chief Financial Officer
Comp: $642.42k
Dr. Veronique Lecault Ph.D. (Age 38)
COO & Director
Comp: $645.07k
Mr. Tryn T. Stimart Esq. (Age 53)
J.D., Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Comp: $644.4k
Mr. Neil Aubuchon M.B.A. (Age 53)
Chief Commercial Officer
Comp: $684.81k
Marcie Thiessen CPA
CGA, Senior Director of Finance & Accounting
Dr. Ester Falconer Ph.D. (Age 48)
Chief Technology Officer
Josephine Hellschlienger Ph.D.
Manager of Investor Relations
Ms. Tiffany Chiu B.Sc.
Ph.D., Vice President of Communications
Graham Craig M.Sc.
Director of Corporate Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ABCL Stock Analysis - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABCL shares.
View ABCL analyst ratings or view top-rated stocks.
What is AbCellera Biologics' stock price target for 2024?: 11 brokerages have issued 1 year target prices for AbCellera Biologics' shares. Their ABCL share price targets range from $6.00 to $34.00. On average, they expect the company's stock price to reach $20.11 in the next year. This suggests a possible upside of 317.2% from the stock's current price.
View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts.
How have ABCL shares performed in 2023?: AbCellera Biologics' stock was trading at $10.13 at the start of the year. Since then, ABCL shares have decreased by 52.4% and is now trading at $4.82.
View the best growth stocks for 2023 here.
When is AbCellera Biologics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our ABCL earnings forecast.
How were AbCellera Biologics' earnings last quarter?: AbCellera Biologics Inc. (NASDAQ:ABCL) announced its earnings results on Thursday, November, 2nd. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company earned $6.60 million during the quarter, compared to analysts' expectations of $11.92 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 10.72% and a negative net margin of 256.27%.

What ETFs hold AbCellera Biologics' stock?: ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).
When did AbCellera Biologics IPO?: (ABCL) raised $356 million in an IPO on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.
Who are AbCellera Biologics' major shareholders?: AbCellera Biologics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (9.03%), Federated Hermes Inc. (1.12%), Lazard Asset Management LLC (1.08%), American Century Companies Inc. (0.33%), Royal Bank of Canada (0.14%) and Schonfeld Strategic Advisors LLC (0.12%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends.
How do I buy shares of AbCellera Biologics?: Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ABCL) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AbCellera Biologics Stock Price, News & Analysis (NASDAQ:ABCL)

AbCellera Biologics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AbCellera Biologics Stock (NASDAQ:ABCL)

ABCL Stock Price History

ABCL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ABCL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™